UIC-2011-132 – Ecumicin: New Tuberculosis Treatment Effective Against Drug-Resistant Strains of TB

Despite the availability of effective treatments, tuberculosis (TB) remains a major public health threat; the rise of multi drug-resistant (MDR) and extensively drug-resistant (XDR) TB is calling for the discovery of new drugs. The UIC Anti-Tuberculosis Screening Program has now evaluated over 65,000 extracts derived from 7,000 actinomycete strains of the Extract Collection of Useful Microorganisms (ECUM) at Myongji University. One priority hit was strain E5123, which was later identified as Nonomuraea sp., based on the strong anti-TB activity of its extract against M. tuberculosis, including strains that are resistant to existing actinomycete-derived antibiotics, and its inhibition of non-replicating M. tuberculosis. This strain was then specially processed to produce the active fractions, resulting in the isolation of a new type of antibiotic called, Ecumicin. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More